Cusatuzumab

CD70 is a ligand expressed on the surface of activated lymphocytes and mature dendritic cells that, in its binding to CD27 receptors, plays an important role in cell proliferation and survival. An overexpression of CD70 can result in the proliferation of malignant cells and has been documented in a variety of solid and hematological malignancies.

Cusatuzumab is a humanized IgG1 antibody targeted against CD70. It is currently being investigated in the Phase 2 CULMINATE trial, in combination with azacitidine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in patients unsuitable for chemotherapy.